Alector Inc
(STU:0Z2)
€
3.98
-0.02 (-0.5%)
Market Cap: 391.41 Mil
Enterprise Value: -93.80 Mil
PE Ratio: 0
PB Ratio: 2.37
GF Score: 62/100 - Q4 2023 Alector Inc Earnings Call TranscriptFeb 27, 2024€5.85 (+1.74%)Earnings
- Alector Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 11, 2023
- Q2 2023 Alector Inc Earnings Call TranscriptAug 03, 2023€6 (-1.64%)Earnings
- Alector Inc at Goldman Sachs Healthcare Conference TranscriptJun 13, 2023
- H.C. Wainwright with Alector TranscriptMay 24, 2023
- Alector Inc at Bank of America Global Healthcare Conference TranscriptMay 10, 2023
- Alector Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 12, 2022
- Alector Inc at Goldman Sachs Global Healthcare Conference TranscriptJun 15, 2022
- Alector Inc at Bank of America Healthcare Conference TranscriptMay 12, 2022
- Alector Inc at Stifel CNS Days (Virtual) TranscriptMar 28, 2022
- Alector Inc at Barclays Global Healthcare Conference TranscriptMar 16, 2022
- Alector Inc to Present New AL001 Data- Conference Call TranscriptMar 15, 2022
- Ultragenyx Pharmaceutical Inc, Alector Inc, Passage Bio Inc, AVROBIO Inc and Annexon Inc in the Orphan CNS Panel at Cowen Health Care Conference (Virtual) TranscriptMar 08, 2022
- Alector Inc to Present to Discuss Data Presented at 2021 Clinical Trials on Alzheimer's Disease Meeting TranscriptNov 12, 2021
- Alector Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 13, 2021
- Alector Inc at Citi BioPharma Conference (Virtual)- Panel: What's Next for Neurodegenerative Diseases TranscriptSep 08, 2021
- Alector Inc to Review the AL001 Phase 2 Results- Conference Call TranscriptJul 29, 2021
- Alector Inc to Discuss Collaboration with GlaxoSmithKline PLC for AL001 & AL101 Call TranscriptJul 02, 2021
- Alector Inc at Bank of America NAPA Healthcare Conference TranscriptJun 14, 2021
- Alector Inc to Host Virtual Key Opinion Leader Event on Frontotemporal Dementia TranscriptJun 11, 2021
- Alector Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 10, 2021
- Alector Inc at Bank of America Global Research Healthcare Conference (Virtual) TranscriptMay 13, 2021
- Alector Inc at Barclays Global Healthcare Conference (Virtual) TranscriptMar 11, 2021
- Alector Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 14, 2020
- Alector Inc at Citi BioPharma Conference (Virtual) TranscriptSep 10, 2020
- Alector Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 10, 2020
- Alector Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) TranscriptMay 13, 2020
- Alector Inc at JPMorgan Healthcare Conference TranscriptJan 16, 2020
- Alector, Inc. - Special Call TranscriptDec 13, 2019
- Alector Inc at Morgan Stanley Healthcare Conference TranscriptSep 10, 2019
- Alector Inc at Bank of America Merrill Lynch Health Care Conference TranscriptMay 15, 2019
Alector Inc at Barclays Global Healthcare Conference (Virtual) Transcript
Mar 11, 2021 / 07:25PM GMT
Release Date Price:
€14.4
(-2.70%)
Carter Lewis Gould
Barclays Bank PLC, Research Division - Senior Analyst
Okay. Good afternoon, and welcome to day 3 of the Barclays Global Healthcare Conference. My name is Carter Gould, senior biopharma analyst here at Barclays, and welcome. We are pleased to welcome Alector to next up for a virtual fireside chat. Representing the company is President and COO, Shehnaaz Suliman. Shehnaaz, welcome very much.
Shehnaaz Suliman
Alector, Inc. - President , COO & Interim Chief Business Officer
Thank you, Carter. It's a pleasure to be here.
Carter Lewis Gould
Barclays Bank PLC, Research Division - Senior Analyst
I believe you're going to make some opening comments, and then we'll hop into Q&A.
Shehnaaz Suliman
Alector, Inc. - President , COO & Interim Chief Business Officer
Absolutely, I'll be delighted to do that. So we, at Alector, have been pioneering immuno-neurology since Arnon Rosenthal founded and CEOs started the company about 8 years ago. And what that
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)